Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Elite Pharmaceuticals Q2 2026 Results: Net Income $17.3M, Up 26.4% YoY

Elite Pharmaceuticals reported net income of $23.2 million for the six months ended September 30, 2026, a significant increase from $7.8 million in the prior year period, largely driven by a $9.8 million gain from the change in fair value of derivative warrants. While six-month revenue slightly decreased to $72.4 million, the company maintained a strong cash position of $34.9 million and significantly reduced its total liabilities from $39.4 million to $22.1 million.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue40.136.3
Gross profit16.014.1
Profit before tax19.715.7
Net income17.313.7
EPS (diluted, $ a share)$0.01$0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+26.4%
Revenue, year on year+10.4%
Gross margin39.9%
Operating margin24.8%
Source

10-Q filed with the SEC, OTC: ELTP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Elite Pharmaceuticals Inc: key numbers

Share price
$0.3700Close, Nov 16
Market cap
$399M
Shares outstanding
1.08BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Elite Pharmaceuticals Inc

All →
5:20 PM ET 8-K
Financial Results

Elite Pharmaceuticals Financial Results

Elite Pharmaceuticals reported financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 10.4% to $40.1 million. The growth was driven by the company's Elite label amphetamine and naltrexone product lines, leading to a 21% increase in operating income to $9.9 million.

Term
Q2 2027
8:13 AM ET 8-K
Leadership Change

Elite Pharmaceuticals Leadership Change

Elite Pharmaceuticals increased its Board of Directors from four to six members and appointed Dr. Aqeel A. Fatmi and John W. LaRocca as new directors. Both appointees bring extensive pharmaceutical industry experience in R&D, operations, and legal governance to the board.

6:05 AM ET Form 4
Insider Buying

Elite Pharmaceuticals Insider Barry H. Dash Buys $26K of Stock

Barry H. Dash bought 100,000 shares of Elite Pharmaceuticals Inc at $0.2598 a share, worth $26K in total on Oct 9, 2026. Shares held after the trade: 3,365,555 (+3.1%).

Value
$26K
Shares
100,000
Price
$0.2598
Holding change
+3.1%
Trade date
Oct 9, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.